Recommendations of the Czech Society of Rheumatology for the treatment of psoriatic arthritis

Czech version

Authors: Pavelka Karel; Mann Heřman; Společnosti České Revmatologické Výbor
Authors‘ workplace: Revmatologický ústav Praha
Published in: Čes. Revmatol., 31, 2023, No. 2, p. 63-74.
Category: Recomendation

Overview

Pavelka K, Mann H, and the Committee of the Czech Society of Rheumatology. Recommendations of the Czech Society of Rheumatology for the treatment of psoriatic arthritis

Psoriatic arthritis (PsA) is a heterogeneous, inflammatory progressive disease affecting mainly the skeleton and skin, but with several other organ manifestations. The Czech Society of Rheumatology issues recommendations for the treatment of PsA, which in principle are based on the EULAR recommendations from 2020. The so-called overarching principles are presented, and the therapy is further divided into four phases (I. to IV.) based on the step-up principle. The treatment of PsA is based on the application of disease-modifying antirheumatic drugs (DMARDs), which are divided into synthetic and biological. Recently, the spectrum of these drugs has expanded considerably, and inhibitors of TNF, IL-17, IL-12/23, IL-23, PDE4, and JAK are now available for the treatment of PsA. The effectiveness of individual DMARDs on different domains of PsA can be different, and therefore it is always advisable to choose this drug individually, according to the predominant manifestation. Individual treatment algorithms regarding the sequence of DMARDs administration are also discussed, as well as strategies when DMARDs fail, as well as strategies for inducing permanent remission. The document must be understood as auxiliary material for the attending rheumatologist and not as a mandatory procedure.

Keywords:

Psoriatic arthritis – biological and targeted drugs – recommendations of the Czech Society of Rheumatology

Sources

Packham J, Tatar B. An overwiew of psoriatic arthritis including clinical manifestations, assessment, diagnostic criteria, investigations, drug management and GRAPPA guidelines. Musculosceletal Care 2022; 20(Suppl 1): S2–S11.

Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and metaananalysis. Rheumatology Int 2021; 41: 275–284.
Taylor W, Gladman D, Helliwell P, Marchesoni A, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–2673.
Felson DT, Anderson J, Boers M, et al. ACR preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheumatism 1995; 38: 727–735.
Fernandez-Sueiro J, Willisch A, Pertéga-Díaz S, Tasende JA, Fernández-López JC, Villar NO, et al. Validity of BASDAI in evaluation of disease activity in axial psoriatic arthritis. Arthritis Care Res 2010; 62: 78–85.
Palominos E, Beckhauser PA, Ribeiro S, Xavier RM, Xavier JW, de Oliveira FB, et al. Correlation of enthesitis indices with disease activity and function in axial and peripheral spondyloarthritis: a crossectional study comparing MASES, SPARCC and LEI. Adv Rheumatol 2019; 59: 23.
Eder L, Mathew AJ, Carron P, Bertheussen H, Cañete JD, Azem M, et al. Management of enthesitis in patients with psoriatic arthritis: an updated literature review informing the 2021 GRAPPA Treatment Recommendations. J Rheumatol 2023; 50(2): 258–264.
Day J, Antony A, Tillett W, Coates LC. The state of the art – psoriatic arthritis outcome assessment in clinical trials and daily practice. Lancet Rheumatol 2022; 4: e220–228.
Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014; 73(6): 1012–1019.
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies, 2019 update. Ann Rheum Dis 2020; 79: 700–712.
Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O‘Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA). A multicentre, open label, randomised controlled trial. Lancet 2015; 386: 2489–2498.
Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L, et al. Etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis: results from randomized, controlled phase III trial. Arthritis Rheumatol 2019; 71: 112–124.
Ramiro S, Smolen JS, Landewé R, van der Heijde D, Dougados M, Emery P, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature review for 2015 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2016; 75: 490–498.
Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, et al. Head to head comparison of the efficacy and safety of ixekizumab and adalimumab in biologic-naive patients with active psoriatic arthritis: 24 –week results of randomised, open label, blinded-assessor trial. Ann Rheum Dis 2020; 79: 123–131.
Mease P, van der Heide D, Landewe R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomized, double blind, phase III FUTURE study. Ann Rheum Dis 2018; 77: 890–897.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, et al. Ixekizumab for the treatment of patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors: results from a 24week randomised, double blind, placebo controlled period of the SPIRIT-P2 phase 3 trial. Lancet 2017; 379: 2317–2327.
Fauny M, Moulin D, D‘Amico F, Netter P, Petitpain N, Arnone D, et al. Paradoxical gastrointestinal effects of interleukin 17-blockers. Ann Rheum Dis 2020; 79: 1132–1138.
McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double blind, placebo controlled PSUMMIT 1 trial. Lancet 2013; 382: 780–789.
Blauvelt A, Reich K, Tsai TF, Tyring S, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis up to 1 year. Results from CLEAR study. J Am Acad Dermatol 2017; 76: 60–69.e9.
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with inadequate response to TNF inhibitors in psoriatic arthritis. N Engl J Med 2017; 377: 1525–1536.
Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, et al. Upadacitinib for psoriatic arthritis refractory tp biologics: SELECT-PsA 2. Ann Rheum Dis 2021; 80: 312–320.
McInnes IB, Ostor AJK, Mease PJ, Tillett W, Baraliakos X, de Vlam K, et al. Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials. RMD Open 2022; 8: e002049.
Ritchlin CT, Helliwell PS, Boehncke WH, Soriano ER, Hsia EC, Kollmeier AP, et al. Guselkumab, an inhibitor of the IL 23 p19 subunit, provides sustained improvement in signs and symtoms of active psoriatic arthritis: 1 year results of phase III randomised study of patients who were biologic – naive or TNFα – experienced. RMD Open 2021; 7: e001457.
Kristensen LE, Keiserman M, Papp K, McCasland L, White D, Lu W, et al. Efficacy and safety of risankizumab for active psoriatic arthritis: a 24–week results from the randomised, double blind, phase 3 KEEPsAKE 1 trial. Ann Rheum Dis 2022; 81: 225– 231.
Behrens F, Cañete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford) 2015; 54: 915–926.
Wells AF, Edwards CJ, Kivitz AJ, Bird P, Nguyen D, Paris M, et al. Apremilast monotherapy in DMARD – naive psoriatic arthritis patients: results of the randomized, placebo controlled trial PALACE 4 trial. Rheumatology (Oxford) 2018; 57: 1253–1263.
Janta I, Martínez-Estupiñán L, Valor L, Montoro M, Baniandres Rodriguez O, Hernández Aragüés I, et al. Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment. Clin Rheumatol 2015; 34: 935–942.
Cantini F, Nannini C, Cassarà E, Kaloudi O, Niccoli L. Uveitis in Spondyloarthritis: An Overview. J Rheumatol Suppl 2015; 93: 27–29.
Petitdemange A, Blaess J, Sibilia J, Felten R, Arnaud L. Shared development of targeted therapies among autoimmune and inflammatory diseases: a systematic repurposing analysis. Ther Adv Musculoskelet Dis 2020; 12: 1759720X20969261.
Law CCY, Kayal M, Mehandru S, Colombel JF. A critical review of upadacitinib for the treatment of adults with moderately to severely active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2023; 17: 109–117.
Gupta S, Syrimi Z, Hughes DM, Zhao SS. Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 2021; 41: 275–284.
Štolfa J, Vencovský J, Pavelka K. Doporučené léčebné postupy pro psoriatickou artritidu. Čes. Revmatol. 2016; 24: 142–152.

Labels

Dermatology & STDs Paediatric rheumatology Rheumatology

EDITORIAL

Prof. MUDr. Milan Adam, DrSc., dr.h.c.

Laudatio for the ninetieth birthday of Zbyněk Hrnčíř, MD, DSc, professor of medicine

Mixed, overlap, and undifferentiated connective tissue diseases in current rheumatology

Chorea associated with antiphospholipid antibodies

Rheumatic diseases and treatment with checkpoint inhibitors

Complicated course of systemic lupus erythematosus

Abstracts of the XIX. seminar of young rheumatologists

Dana Němcová, MD celebrated a significant life anniversary

Life anniversary of Šárka Forejtová, MD

Article was published in

Czech Rheumatology

2023 Issue 2